Thalidomide to Patients With Previously Untreated Multiple Myeloma

Phase 3 Completed 363 enrolled Norwegian University of Science and Technology Nordic Myeloma Study Group, Germany · collab The Research Council of Norway · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the effect of thalidomide in patients with multiple myeloma. The patients receive either thalidomide or a placebo tablet (neither patient nor doctor know which of these are given) in addition to the ordinary chemotherapeutic drug against multiple myeloma. We will find out for how long time the patients will stay free of the disease and for how long time they will live, and can evaluate whether thalidomide is a beneficial drug against this disease.

Timeline

Start: 2002-01
Primary completion: 2007-04
Completion: 2007-04

Publications

Results Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Bjorkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukas E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sorbo JH, Wisloff F, Juliusson G, Turesson I; Nordic Myeloma Study Group. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010 Sep 2;116(9):1405-12. doi: 10.1182/blood-2009-08-237974. Epub 2010 May 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Thalidomide	Other / unclassified	200 mg	—

Thalidomide to Patients With Previously Untreated Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications